HRSA-25-054: Ryan White HIV/AIDS Program Part A HIV Emergency Relief Grant Program
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of Health Resources and Services Administration notices from 2024.
Health Resources and Services Administration offered grants to the applicants described in the notice. It expected to make about 52 awards worth $654 million in total. Applications closed on October 1, 2024.
From the official notice on Grants.gov, last changed July 31, 2024. Checked November 7, 2026.
- Total funding$654 million
- Expected awards52
- Cost sharingNot required
- Funding typeGrant
Other notices with this title
| Notice | Posted | Deadline | Status |
|---|---|---|---|
| HRSA-22-018 | June 11, 2021 | Closed October 6, 2021 | Closed |
Key dates
| Posted | July 3, 2024 |
|---|---|
| Deadline | October 1, 2024 |
Who can apply
This opportunity was open to the applicants described in the notice.
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
RWHAP Part A recipients that are classified as an EMA or as a TGA and continue to meet the status as an eligible area as defined in the statute are eligible to apply for these funds. Eligibility for RWHAP Part A grants is based in part on the number of confirmed AIDS cases within a statutorily specified metropolitan area. The Secretary uses the Office of Management and Budgets (OMB) census-based definitions of a Metropolitan Statistical Area (MSA) in determining the geographic boundaries of a RWHAP metropolitan area. HHS utilizes the OMB geographic boundaries that were in effect when a jurisdiction was initially funded under RWHAP Part A. For all newly eligible areas, the boundaries are based on current OMB MSA boundary definitions. EMA Status: EMAs must have more than 2,000 cases of AIDS reported and confirmed during the most recent five calendar years, and have a population of at least 50,000. For three consecutive years, the recipients must not have fallen below the required incidence levels already specified and required prevalence level of 3,000 living cases of AIDS. TGA Status: TGAs must have at least 1,000, but fewer than 2,000 cases of AIDS reported and confirmed during the most recent five calendar years for which such data are available and have a population of at least 50,000. For three consecutive years, recipients must not have fallen below both the required incidence levels already specified and required prevalence level of 1,500 or more living cases of AIDS. For a TGA with five percent or less of the total amount from grants awarded to the area under Part A unobligated, as of the end of the most recent FY, the required prevalence is at least 1,400 (and fewer than 1,500) living cases of AIDS. This competition is open to eligible Part A jurisdictions to provide comprehensive primary health care and support services for people with HIV in their service areas as listed in Appendix B. The supplemental portion of the award is open to all eligible Part A jurisdictions that did not have an unobligated balance of greater than five percent in a previous fiscal year, which will be determined annually and communicated to applicable recipients. Native American tribal governments and tribal organizations are not eligible.
Is this a realistic fit?
- No cost sharing or match is required.
What the grant funds
This notice announces the opportunity to apply for funding under the Ryan White HIV/AIDS Program (RWHAP) Part A HIV Emergency Relief Grant Program. The purpose of this program is to provide direct financial assistance to an eligible metropolitan area (EMA) or transitional grant area (TGA) that has been severely affected by the HIV epidemic. Grant funds assist eligible jurisdictions to develop or enhance access to comprehensive, high quality, community-based care for people with HIV through the provision of grant funds. The goal is to provide optimal HIV care and treatment for people with HIV and improve their medical outcomes. RWHAP Part A recipients must use these funds to provide comprehensive primary health care and support services throughout the entire designated geographic service area. Your application must address the entire service area, as defined in Appendix B. Comprehensive HIV care consists of core medical services and support services that enable people with HIV to access and remain in HIV primary medical care to improve their health outcomes. Based on an annual assessment of the services and gaps in the HIV care continuum within a jurisdiction, HIV Planning Councils/Planning Bodies (PCs/PBs) and RWHAP recipients identify specific service categories to fund. Activities in each funded service category should lead to improvements in HIV care continuum outcomes. RWHAP Part A EMAs and TGAs must use grant funds to support, further develop, and/or expand systems of care to meet the needs of people with HIV within the EMA/TGA and strengthen strategies to reach disproportionately impacted subpopulations. The Health Resources and Services Administration (HRSA) HIV/AIDS Bureau (HAB) requires EMAs/TGAs to collect and analyze data to identify needs, set priorities, make allocations, and validate the use of RWHAP funding. Your application should describe how you have used data to develop and enhance the system of care in your jurisdiction. HRSA encourages innovation and collaboration with other agencies and organizations to maximize impact on health outcomes and effectively meet the needs of people with HIV within the EMA/TGA. For more details, see Program Requirements and Expectations.
Who has won HIV Emergency Relief Project Grants grants before
From fiscal 2021 to 2025, HIV Emergency Relief Project Grants (93.914) awarded $3.5 billion across 140 grant awards, an average of $25.2 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| City of New York | New York | 2 | $504 million |
| County of Los Angeles | California | 2 | $251 million |
| County of Fulton | Georgia | 2 | $169 million |
| District of Columbia, Government of | District of Columbia | 2 | $161 million |
| Harris County | Texas | 2 | $143 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is HRSA-25-054 still open?
No. It closed on October 1, 2024.
Who can apply for Ryan White HIV/AIDS Program Part A HIV Emergency Relief Grant Program?
Health Resources and Services Administration accepted applications from the applicants described in the notice. The notice adds further conditions, so read its eligibility section.
What is the deadline for Ryan White HIV/AIDS Program Part A HIV Emergency Relief Grant Program?
Closed October 1, 2024. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
About $654 million in total across about 52 awards.
Who has won HIV Emergency Relief Project Grants grants before?
The largest recipients over five fiscal years were City of New York, County of Los Angeles, County of Fulton. The program made 140 awards worth $3.5 billion in that time.
Similar open grants
- Single Source for the Continuation of the Caring for OutPatiEnts after Acute Kidney Injury (COPE-AKI) Scientific and Data Research Center (U01 Clinical Trial Required)
- Single Source for the Continuation of the Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Center (Collaborative U01 Clinical Trial Not Allowed)
- Data Coordinating Center for the Aging and Alzheimer’s Disease Mouse Brain Atlas (AD-MBA) (U24 Clinical Trial Not Allowed)
- Amyotrophic Lateral Sclerosis (ALS) Intermediate Patient Population Expanded Access (U01 Clinical Trial Required)
- Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed)
- Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed)